天眼查App显示，近日，唐山高新区战新产业发展基金（有限合伙）成立，执行事务合伙人为北京骐健私募基金管理有限公司，出资额5.01亿人民币，经营 范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由唐山高新区国有控股集团有限责任公司、北京骐健私募基金管理 有限公司、河北省机器人产业基金（有限合伙）共同出资。 | ●大眼管 | | 都在用的 商业 查 询 工 具 | 章公司 童老板 童关系 查风险 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 国家中小企业发展子基金旗下机构 | 唐山高新区战新产业发展基金（有限合伙） | × | 天眼一下 | 船 应用 ▼ | 商务合作 | | 基本信息 3 | | 法律诉讼 | 经营风险 | 经营信息 | | 公司发展 | 知i | | 合伙人信息 3 ⑦ ● 品 股权结构 | | | | | | | | | 序号 | | | 合伙人名称 | | | 出资比例÷ | 认缴出资额 | | | | 北京骐健私募基金管理有限公司 器 | | | | | | | 1 | 具 ...

天眼查App显示，8月6日，唐山高新区战新产业发展基金（有限合伙）成立，执行事务合伙人为北京骐 健私募基金管理有限公司，出资额5.01亿人民币，经营范围为以私募基金从事股权投资、投资管理、资 产管理等活动。合伙人信息显示，该基金由唐山高新区国有控股集团有限责任公司、北京骐健私募基金 管理有限公司、河北省机器人产业基金（有限合伙）共同出资。 ...

Core Viewpoint - The medical device sector is experiencing a rise, with notable increases in stocks such as United Imaging Healthcare, New Industry, BGI Genomics, and Jiuan Medical, all rising over 3% [1] Group 1: Stock Performance - The ETF tracking the CSI All Share Medical Device Index has increased by approximately 3% [1] - Specific ETFs in the medical device sector have shown significant gains, with the Medical Device ETF Fund at 0.830, up 3.23%, and the Medical Device Index ETF at 0.588, up 3.16% [2] Group 2: Future Opportunities - Analysts indicate that increasing internationalization will provide more investment opportunities in the medical device sector, with several companies expected to see high growth in international business by 2025 [2] - The performance of Hong Kong's medical device stocks has been strong this year, which may positively influence the A-share market, suggesting that investment opportunities in both A-shares and Hong Kong's medical device sector will continue to emerge [2]

Group 1 - The A-share pharmaceutical sector is experiencing a rebound, with the Medical Innovation ETF (516820.SH) rising by 0.78% [1] - Key stocks such as Antu Bio (603658) increased by 6.18%, Mindray Medical (300760) by 2.61%, and Aimeike (300896) by 1.88% [1] - The Shanghai Regulatory Bureau and seven other ministries issued measures to promote the high-quality development of commercial insurance to support pharmaceutical innovation, encouraging the establishment of "patient capital" for long-term support of innovative drug research and development [1] Group 2 - The new measures have attracted over 100 drug applications for inclusion in the commercial health insurance innovative drug catalog, shifting the industry from a "single-driver" model to a "dual-driver" model of "medical insurance + commercial insurance" [1] - The national unified medical insurance big data platform, covering 1.3 billion insured individuals and over 300,000 types of drugs and consumables, is seen as a significant support for the development of the industry [1] - The platform aids in quickly analyzing clinical needs, enhancing drug value assessment, and accelerating the inclusion of innovative drugs into medical insurance, thus promoting the development of commercial insurance [1] Group 3 - Market dynamics are shifting, with funds moving from high-valued sectors to reasonably valued ones, leading to a gradual rebound of core assets at the bottom [2] - The medical innovation sector, including CXO (WuXi AppTec/TigerMed), medical devices (Mindray), and medical consumption (Aier Eye Hospital/Aimeike), is highlighted as having core assets that are significantly undervalued [2] - Weak U.S. economic and employment data may accelerate the Federal Reserve's rate cuts, enhancing global liquidity and benefiting technology stocks, presenting a good opportunity for investment in the medical innovation ETF (516820) [2]

（文章来源：证券日报） 证券日报网讯 8月6日晚间，新产业发布公告称，近日，公司收到了广东省药品监督管理局颁发的1项 《医疗器械注册证》，产品名称及型号：电解质分析仪（型号：BiossaysE6Plus）。 ...

Group 1 - The core viewpoint of the article is the issuance of measures to promote the high-quality development of commercial health insurance to support innovation in the biopharmaceutical industry [1] Group 2 - The measures aim to broaden the service population of commercial health insurance, focusing on the needs of the elderly, children, and patients with chronic diseases [1] - Insurance institutions are encouraged to include elderly individuals and those with pre-existing conditions in their coverage, based on controllable risks and commercial sustainability [1] - The use of big data and industry experience data is recommended to reasonably determine insurance product rates and to relax underwriting conditions [1] - There is an emphasis on providing diversified customized services and increasing health coverage for specific groups such as new citizens and those in emerging industries and business formats [1]

Core Viewpoint - The company has received a medical device registration certificate for its electrolyte analyzer, indicating a significant step in its product development and regulatory compliance [1] Company Summary - The company, 新产业 (300832), has been granted a medical device registration certificate by the Guangdong Provincial Drug Administration for its product, the electrolyte analyzer (model: Biossays E6 Plus) [1]

（文章来源：每日经济新闻） 2024年1至12月份，新产业的营业收入构成为：体外诊断占比99.82%，其他业务占比0.18%。 新产业（SZ 300832，收盘价：55.7元）8月6日晚间发布公告称，近日，深圳市新产业生物医学工程股 份有限公司收到了广东省药品监督管理局颁发的1项《医疗器械注册证》。产品名称为"电解质分析 仪"。 ...

证券代码：300832 证券简称：新产业 公告编号：2025-059 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收 到了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： 上述医疗器械注册证的取得，丰富了公司电解质分析仪器产品线，将对公 司发展具有正面影响，但对近期的生产经营和业绩不会产生重大影响，敬请投 资者给予关注并注意投资风险。 特此公告。 深圳市新产业生物医学工程股份有限公司 一、医疗器械注册证的具体情况 | 产品名称 | 注册 | 注册证编号 | 注册证有效期 | 适用范围 | 及型号 | 分类 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 用于检测人全血、血清 | +、Na+、Cl-、Li+、 | 电解质分析仪 | 中 | K | | | | | | | | | | | | | | 粤械 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Shenzhen New Industry Biomedical Engineering Co., Ltd. in the medical device sector, showcasing its financial results and industry rankings [1][2] - As of August 6, the company's stock closed at 55.7 yuan, with a rolling PE ratio of 23.79 times and a total market capitalization of 43.765 billion yuan [1] - The average PE ratio for the medical device industry is 53.93 times, with a median of 37.81 times, placing the company at the 50th position within the industry [1][2] Group 2 - The company reported a revenue of 1.125 billion yuan for Q1 2025, reflecting a year-on-year increase of 10.12%, and a net profit of 438 million yuan, up 2.65% year-on-year, with a gross profit margin of 68.01% [1] - A total of 48 institutions hold shares in the company, with 48 funds collectively owning 33.4155 million shares valued at 1.895 billion yuan [1] - The company has been recognized with the "National Brand Gold Award" for medical equipment in 2024, achieving the top rank in customer satisfaction metrics among tertiary hospitals [1]